Torres-Márquez M E, Villalobos-Molina R, García-Sáinz J A
Departamento de Bioenergética, Instituto de Fisiología Celular, UNAM, Mexico City, D.F.
Eur J Pharmacol. 1991 Mar 25;206(3):199-202. doi: 10.1016/s0922-4106(05)80019-7.
The effect of several alpha 1 adrenoceptor antagonists on the alpha 1-adrenoceptor-mediated stimulation of phosphatidylinositol labeling was studied comparatively in rat hepatocytes and rabbit aorta. It was observed that 5-methyl urapidil and WB 4101 were much more potent in rabbit aorta than in hepatocytes. The orders of potency were prazosin much greater than 5-methyl urapidil greater than or equal to WB 4101 in liver cells and WB 4101 greater than or equal to 5 methyl urapidil = prazosin in aorta. Treatment with chlorethylclonidine inhibited 70-80% of the stimulation of labeling induced by epinephrine in rat liver, but only 30-40% of that in aorta. Our data suggest the existence of two pharmacologically distinct receptors in these tissues i.e.m alpha 1A-adrenoceptors in aorta and alpha 1B in liver cells.
在大鼠肝细胞和兔主动脉中比较研究了几种α1肾上腺素能受体拮抗剂对α1肾上腺素能受体介导的磷脂酰肌醇标记刺激的影响。观察到,5-甲基乌拉地尔和WB 4101在兔主动脉中的作用比在肝细胞中强得多。在肝细胞中,效力顺序为哌唑嗪远大于5-甲基乌拉地尔大于或等于WB 4101;在主动脉中,效力顺序为WB 4101大于或等于5-甲基乌拉地尔 = 哌唑嗪。用氯乙可乐定处理可抑制大鼠肝脏中肾上腺素诱导的标记刺激的70 - 80%,但在主动脉中仅抑制30 - 40%。我们的数据表明,在这些组织中存在两种药理学上不同的受体,即主动脉中的mα1A - 肾上腺素能受体和肝细胞中的α1B受体。